{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 71/80', '10.5.', 'DATA QUALITY CONTROL / ASSURANCE', '10.5.1. Monitoring', 'This clinical study will be monitored by sponsor representatives according to their current', 'Standard Operating Procedures for the monitoring of clinical studies as described in the', 'monitoring plan.', 'To guarantee adequate protection of the subjects and to guarantee the quality of the data, the', 'sponsor will ensure oversight of any clinical study-related duties and functions carried out on', 'its behalf, including clinical study-related duties and functions that are subcontracted to another', \"party by the sponsor's contracted CRO(s).\", '10.5.2. Audit and Inspection', 'To ensure compliance with relevant regulations, an independent quality assurance', 'representative, regulatory authorities and/or IECs/IRBs may review this clinical study. This', 'implies that auditors/inspectors will have the right to inspect the clinical study center(s) at any', 'time during and/or after completion of the clinical study and will have access to the data', \"generated during the clinical study, source documents, and subject's files. By participating in\", 'this clinical study, investigators agree to this requirement.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 72/80', 'REFERENCES', 'Allanore, T., Distler, O., Jagerschmidt, A., et al. (2018). Double-blind, Randomized, 8-week', 'Placebo-controlled followed by a 16-week open label extension study, with the LPA1 receptor', 'antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis', 'Rheumatol, Epub ahead of print.', 'Bandoh, K., Aoki, J., Taira, A., et al. (2000). Lysophosphatidic acid (LPA) receptors of the', 'EDG family are differentially activated by LPA species. Structure-activity relationship of', 'cloned LPA receptors. FEBS Lett, 478(1-2), 59-65.', 'ICH E10. (2000). Choice of control group and related issues in clinical trials E10.', 'Khanna, D., Furst, D., Clements, P., et al. (2017). Standardization of the modified Rodnan', 'skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord, 2(11),', '11-18.', 'Khanna, D., Furst, D., Hays, R., et al. (2006). Minimally important difference in diffuse', 'systemic sclerosis: results from the D-penicillamine study. Ann Rheum Diss, 65(10), 1325-', '1329.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 73/80', 'Tanaka, M., Okudaira, S., Kishi, Y., et al. (2006). Autotaxin stabilizes blood vessels and is', 'required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem,', '281(35), 25822-25830.', 'Tsuda, S., Okudaira, S., Moriya-Ito, K., et al. (2006). Cyclic phosphatidic acid is produced by', 'autotaxin in blood. J Biol Chem, 281(36), 26081-26088.', 'Van den Hoogen, F., Khanna, D., Fransen, J., et al. (2013). 2013 classification criteria for', 'systemic sclerosis: an American College of Rheumatology/European League against', 'Rheumatism collaborative initiative. Arthritis Rheum, 65(11), 2737-2747.', 'Woosley, RL., Heise, CW., Romero, KA. (2018). QTdrugs List. Retrieved July 24, 2018,', 'from www.CredibleMeds.org.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}